IQVIA Holdings Inc. IQV SPX
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Strong return on equity of 22.5%.
- Generates positive free cash flow.
CONS
- Trading 25.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IQV IQVIA Holdings Inc. SPX | 182.21 | 22.63 | $30.41B | - | 10.74% | 22.49% | 4.21% | 7.62% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 3.83B | 4.02B | 4.10B | 4.36B | 4.15B |
| Cost of Revenue | 2.53B | 2.69B | 2.73B | 2.93B | 2.80B |
| Gross Profit | 1.30B | 1.32B | 1.37B | 1.44B | 1.35B |
| Operating Expenses | 773.00M | 785.00M | 800.00M | 785.00M | 790.00M |
| Operating Income | 525.00M | 538.00M | 573.00M | 651.00M | 565.00M |
| EBITDA | 753.00M | 781.00M | 883.00M | 1.05B | 808.00M |
| Interest Expense | 165.00M | 182.00M | 189.00M | 193.00M | 192.00M |
| Pretax Income | 323.00M | 323.00M | 408.00M | 537.00M | 328.00M |
| Tax Provision | 61.00M | 56.00M | 76.00M | 59.00M | 59.00M |
| Net Income | 249.00M | 266.00M | 331.00M | 514.00M | 274.00M |
| Diluted EPS | 1.40 | 1.54 | 1.93 | 2.99 | 1.61 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 14.41B | 14.98B | 15.40B | 16.31B |
| Cost of Revenue | - | 9.38B | 9.74B | 10.03B | 10.88B |
| Gross Profit | - | 5.03B | 5.24B | 5.38B | 5.43B |
| Operating Expenses | - | 3.20B | 3.18B | 3.11B | 3.14B |
| Operating Income | - | 1.83B | 2.06B | 2.27B | 2.29B |
| EBITDA | - | 2.91B | 3.26B | 3.45B | 3.46B |
| Interest Expense | - | 416.00M | 672.00M | 670.00M | 729.00M |
| Pretax Income | - | 1.36B | 1.46B | 1.67B | 1.59B |
| Tax Provision | - | 260.00M | 101.00M | 301.00M | 252.00M |
| Net Income | - | 1.09B | 1.36B | 1.37B | 1.36B |
| Diluted EPS | - | 5.72 | 7.29 | 7.49 | 7.84 |
Compounded Sales Growth
| 5 Years: | 4.21% |
| 1 Year: | 8.40% |
Compounded Profit Growth
| 5 Years: | 7.62% |
| 1 Year: | 15.00% |
Stock Price Performance
| 1 Year: | +29.84% |
| 6 Months: | -21.43% |
| 3 Months: | +1.90% |
| 1 Month: | +16.31% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 25.34B | 26.68B | 26.90B | 29.94B |
| Current Assets | - | 4.98B | 5.60B | 5.83B | 6.25B |
| Cash & Equivalents | - | 1.22B | 1.38B | 1.70B | 1.98B |
| Inventory | - | - | - | - | - |
| Receivables | - | 1.33B | 1.47B | 1.39B | 1.67B |
| Total Liabilities | - | 19.57B | 20.57B | 20.83B | 23.31B |
| Current Liabilities | - | 5.58B | 6.49B | 6.96B | 8.34B |
| Long Term Debt | - | 12.60B | 12.96B | 12.84B | 13.88B |
| Total Debt | 12.44B | 13.01B | 13.90B | 14.16B | - |
| Total Equity | - | 5.76B | 6.11B | 6.07B | 6.50B |
| Shares Outstanding | - | 256.40M | 257.20M | 258.20M | 259.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 2.26B | 2.15B | 2.72B | 2.65B |
| Investing Cash Flow | - | -2.01B | -1.60B | -1.44B | -2.31B |
| Financing Cash Flow | - | -329.00M | -382.00M | -878.00M | -150.00M |
| Capital Expenditure | - | -674.00M | -649.00M | -602.00M | -603.00M |
| Free Cash Flow | - | 1.59B | 1.50B | 2.11B | 2.05B |
| Net Change in Cash | - | -75.00M | 164.00M | 394.00M | 199.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 34.9% | 35.0% | 34.9% | 33.3% |
| Operating Margin % | - | 12.7% | 13.8% | 14.7% | 14.0% |
| Net Margin % | - | 7.6% | 9.1% | 8.9% | 8.3% |
| ROE % | - | 18.9% | 22.2% | 22.6% | 20.9% |
| ROCE % | - | 9.2% | 10.2% | 11.4% | 10.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.00% | 15.03M | $2.74B |
| 2 | Harris Associates L.P. | 7.30% | 12.18M | $2.22B |
| 3 | Vanguard Capital Management LLC | 6.61% | 11.03M | $2.01B |
| 4 | Vanguard Portfolio Management LLC | 4.54% | 7.58M | $1.38B |
| 5 | State Street Corporation | 4.48% | 7.48M | $1.36B |
| 6 | JPMORGAN CHASE & CO | 3.24% | 5.41M | $985.34M |
| 7 | Artisan Partners Limited Partnership | 3.03% | 5.06M | $921.78M |
| 8 | Geode Capital Management, LLC | 2.67% | 4.46M | $813.21M |
| 9 | Boston Partners | 2.54% | 4.24M | $772.38M |
| 10 | Invesco Ltd. | 1.95% | 3.26M | $594.33M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IQV